Drugs / LCAR-BCDR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05376345 | Sep 2022 → May 2025 | refractory plasma cell neoplasm | Weijun Fu | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-BCDR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05376345 ↗ |
| Modality | Cell therapy | “LCAR-BCDR cell preparations” NCT05376345 ↗ |